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Management of Ventricular Arrhythmias
A Trial-based Approach
Patrick J. Welch, MD, Richard L. Page, MD, FACC, Mohamed H. Hamdan, MD, FACC
Dallas, Texas
Sudden cardiac death accounts for approximately 300,000 deaths annually in the U.S., and
most of these are secondary to ventricular tachycardia (VT) and fibrillation in patients with
coronary artery disease. Most patients with cardiac death die before reaching the hospital,
which brought about a tremendous amount of research focused at identifying patients at high
risk. Several trials were initiated to test the effectiveness of various therapeutic measures in
these high-risk patients. A history of myocardial infarction, depressed left ventricular function
and nonsustained VT have all been identified as independent risk factors for future
arrhythmic death. Similarly, patients with a history of sustained VT or a history of sudden
cardiac death are a high-risk group and should be aggressively evaluated and treated. The
purpose of this article is to discuss risk stratification and primary prevention of sustained
ventricular arrhythmias. We also review the recent secondary prevention trials and discuss the
options available in the management of patients with sustained ventricular arrhythmias. (J
Am Coll Cardiol 1999;34:621–30) © 1999 by the American College of Cardiology
Sudden cardiac death, defined as instantaneous death within
1 h of an abrupt change in clinical status, accounts for ap-
proximately 300,000 deaths in the U.S. annually (1). Most
sudden deaths are due to ventricular tachycardia (VT) or
ventricular fibrillation (VF). Although some sudden death
victims have no overt evidence of cardiovascular disease,
patients with existing heart disease are at higher risk. Many
cardiac diseases may increase the risk of ventricular arrhyth-
mias and sudden death, but acute ischemia and prior
myocardial infarctions (MIs) are by far the most common,
with over 50% of all sudden cardiac deaths occurring in
patients with coronary artery disease (2). This review ad-
dresses the management of ventricular arrhythmias in pa-
tients having coronary artery disease, with an emphasis on
some of the latest clinical trials. In the first section, we will
discuss risk stratification and primary prevention of sus-
tained ventricular arrhythmias, and in the second section,
we summarize the options available in the management of
sustained ventricular arrhythmias with emphasis on the
recent secondary prevention trials.
RISK STRATIFICATION AND
PRIMARY PREVENTION OF
SUSTAINED VENTRICULAR ARRHYTHMIAS
Most sudden cardiac deaths are the result of sustained
ventricular tachyarrhythmias, but unfortunately, most pa-
tients with sudden death die before reaching the hospital.
Because the number of patients surviving to hospitalization
with sustained ventricular arrhythmias represent a fraction
of the patients who may be at risk for an arrhythmic event,
a tremendous amount of research has focused on developing
risk stratification methods to identify the patient at highest
risk. A number of trials have been performed to test the
effectiveness of various prophylactic treatment strategies for
high-risk patients. Because patients with coronary artery
disease represent most high-risk patients, many large clin-
ical trials have excluded other patient groups. In the section
that follows, we summarize the data for risk stratification
and primary prevention of sustained ventricular arrhythmias
in patients with coronary artery disease.
Risk stratification. Many articles published before the
widespread use of thrombolytic therapy and beta-adrenergic
blocking agents, describe risk factors for sudden death in
patients with previous MIs. The risk of sudden death after
a MI is approximately 5% per year for at least three to five
years after an infarction. The risk is proportional to the
degree of left ventricular dysfunction, with a left ventricular
ejection fraction below 40% the best predictor of an adverse
long-term outcome (3–7). Asymptomatic ventricular ar-
rhythmias, including premature ventricular contractions
(PVCs) and nonsustained VT (three beats to 30 s of VT),
are also valuable for predicting outcome in patients with
coronary artery disease. Isolated ventricular ectopy is com-
mon after MI, and up to 80% of patients will have some
ectopy present on a 24-h ambulatory (Holter) monitor (8).
A report of the 1,640 patients in the placebo arm of the
Beta-Blocker Heart Attack Trial (B-HAT) who were not
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treated with beta-blockers identified frequent ventricular
ectopy (.10 PVCs/h) and nonsustained VT as independent
risk factors for sudden death (8). Many other studies have
confirmed that nonsustained VT and frequent, multiple or
complex ventricular extrasystoles detected by ambulatory
monitoring are significant, independent risk factors for
sudden death (3). In general, more frequent or complex
ventricular ectopy is associated with a worse prognosis.
Most studies indicate that the risk of sudden death begins to
rise if greater than three PVCs/h are present, and rises
sharply if .10 PVCs/h are present (9–11). Nonsustained
VT has also been shown to be a predictor of sudden death,
particularly in patients with left ventricular dysfunction (6).
Because nonsustained ventricular arrhythmias and left ven-
tricular dysfunction are independent risk factors, patients
with both have the worst long-term survival (odds ratio for
sudden death 2.35 to 4.7) (Fig. 1) (6,7,12).
Signal-averaged electrocardiography (SAECG) is a com-
monly used noninvasive method for risk stratification. An
abnormal signal average electrocardiogram correlates with
the presence of both clinical and laboratory-induced VT in
patients presenting with sustained VT. The SAECG has
also been used to risk stratify patients after MI, and a
negative predictive value of $90% has been demonstrated.
However, the positive predictive value for death or an
arrhythmic event is only 16% to 31% (13–16). When
SAECG is used in patients with known left ventricular
dysfunction, the sensitivity, specificity and positive predic-
tive value are all enhanced. Patients with left ventricular
ejection fractions ,40% and a positive SAECG plus fre-
quent ectopy or nonsustained VT on Holter are at very high
risk for suffering arrhythmic events during a two-year follow
up (45% to 50%) (17). Thus, the results of ambulatory
monitoring and signal-averaged electrocardiograms are per-
haps best interpreted in combination with a determination
of left ventricular function to identify those patients at
highest risk of arrhythmic events or sudden death after MI
(18). Further evaluation of this approach is necessary, and
will be available after analysis of the Multicenter Unsus-
tained Tachycardia Trial (MUSTT) study (see following
section).
Evidence to date has shown that signal-averaged electro-
cardiography and Holter monitoring combined with a
determination of ejection fraction have high negative pre-
dictive value but relatively poor positive predictive value
(19). Because of low positive predictive value, the results of
these noninvasive tests frequently cause referral for invasive
electrophysiologic study using programmed electrical stim-
ulation. Programmed stimulation is both a sensitive and
specific technique for inducing monomorphic VT in pa-
tients with coronary artery disease; such patients who
present with this arrhythmia have the VT reproduced in
over 90% of cases (20). It has also been used to risk stratify
patients after MI, with sustained VT induced in 21% to
45% of all patients (21–23). Use of a full programmed
electrical stimulation protocol with three extrastimuli in-
creases inducibility rates up to 45% (24). Patients without
inducible ventricular arrhythmias have event-free survival
rates ranging from 88% to 96%, regardless of the presence of
left ventricular dysfunction, nonsustained ventricular ar-
rhythmias or a positive signal averaged electrocardiogram
(25). This demonstrates the excellent specificity and nega-
tive predictive value of programmed electrical stimulation in
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Figure 1. Kaplan-Meier survival curves for post-MI patients
cross-classified by ejection fraction (EF, ,30% or over) and
presence or absence of nonsustained VT. (Reprinted from Amer-
ican Journal of Cardiology 1986;58:1151–60, with permission from
Excerpta Medica, Inc.)
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this population (Fig. 2). The positive predictive value of
programmed stimulation is more difficult to quantify. Ex-
cept for the MUSTT (see following section), which is
currently in the follow-up phase, no study to date has
randomized a large group of post-MI patients with induc-
ible VT to treatment or placebo. Most reported series of
post-MI patients having inducible VT have been uncon-
trolled studies without placebo treatment groups, and vir-
tually all patients have received antiarrhythmic therapy. The
estimate of positive predictive value is confounded by the
introduction of treatment to all patients at risk and by the
possibility of proarrhythmic effects of the drugs. Given these
limitations, the positive predictive value of programmed
stimulation has never been estimated to exceed 49% over a
two- to five-year follow-up (25).
Trials for primary prevention of sustained ventricular
arrhythmias. In the past decade, a number of published
studies have investigated the benefit of prophylactic antiar-
rhythmic therapy for patients with prior MIs with or
without nonsustained ventricular arrhythmias or left ven-
tricular dysfunction. The multicenter Cardiac Arrhythmia
Suppression Trial (CAST) was designed to test the hypoth-
esis that suppression of ventricular ectopy on Holter mon-
itor with class IC agents conferred a survival benefit (the
“PVC suppression hypothesis”) (26). Suppression was eval-
uated using encainide, flecainide or moricizine in an open-
label titration period, and only patients with adequate
suppression were randomized to drug or placebo. In 1989,
the safety and monitoring committee terminated the study
prematurely because of excess deaths from arrhythmias and
nonfatal cardiac arrests in the flecainide and encainide
treatment groups (27). The study continued as CAST II,
but was also terminated because of a lack of demonstrated
benefit with moricizine and possible increased mortality in
the open-label titration phase (26) (see Table 1). The results
of the CAST studies led to a significant decrease in the use
of class IC agents and a growing interest in class III agents.
Sotalol was first tested in patients with a history of MI in
1982. In this trial (28), patients began receiving either
d,l-sotalol 320 mg per day or placebo on day 5 to 14
post-MI and were followed for one year. Patients treated
with sotalol had an 18% reduction in total mortality (7.3%
in the sotalol group vs. 8.9% in the placebo group, relative
risk 5 0.81). This reduction in mortality rate, however, may
have been due solely to the beta-blocking activity of the
drug. The Survival with Oral d-Sotalol (SWORD) trial was
designed to test whether the pure d-stereoisomer of sotalol,
which retains the class III potassium-channel blocking
activity but lacks beta-blocking activity, would prolong
survival in patients with depressed left ventricular function
after MI. The trial was terminated prematurely due to
excess mortality in the treatment group, which appeared to
be secondary to enhanced arrhythmic death. The authors
concluded that d-sotalol did not reduce mortality and may
be associated with increased mortality (29). Of note, mor-
tality was highest in low-risk patients and minimal in
high-risk patients. The increase in mortality in the low-risk
group was probably secondary to drug proarrhythmia. Both
sotalol trials are summarized in Table 1.
Several studies have examined the benefit of amiodarone
for patients with prior MI. The Basel Antiarrhythmic Study
of Infarct Survival (BASIS) randomized post-MI patients to
one of the following treatments for one year: 1) individual-
ized antiarrhythmic drugs, starting with class IA agents; 2)
low-dose amiodarone, or 3) no antiarrhythmic therapy (30).
End points were total mortality and arrhythmic events.
Using an intention-to-treat analysis, patients receiving amio-
darone had less arrhythmic events and a higher probability
of survival (31,32). The Polish Amiodarone Pilot Study was
designed to test the effect of amiodarone on mortality,
ventricular arrhythmias and clinical complications in
post-MI patients unable to take beta-blocking drugs (33).
After a one-year follow-up, patients treated with amioda-
rone had a nonsignificant improvement in total survival
compared with patients receiving placebo, although there
was a statistically significant difference in cardiac mortality
rates between the two groups. The frequency of ventricular
arrhythmias was significantly reduced by amiodarone (33).
In the Canadian Amiodarone Myocardial Infarction Ar-
rhythmia Trial (CAMIAT) pilot study (34), 77 post-MI
patients with 10 or more PVCs/h were randomized to
amiodarone versus placebo. At the 2-year follow up, the
incidence of arrhythmic death or resuscitated VF was 6% in
the amiodarone group and 14% in the placebo group.
Similarly, the all-cause mortality rate was 10% in the
amiodarone group versus 21% in the placebo group. The
encouraging results of these early studies led to the design of
two large trials to test the benefit of amiodarone in post-MI
patients: the European Myocardial Infarct Amiodarone
Trial (EMIAT), and the Canadian Amiodarone Myocardial
Infarction Arrhythmia Trial (CAMIAT).
The objective of EMIAT was to assess the effect of
amiodarone on all-cause mortality and arrhythmic death in
Figure 2. Survival without subsequent arrhythmia in patients with
coronary artery disease and nonsustained VT, who had negative
electrophysiology studies. Adapted from references 21–23 and 50.
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patients with left ventricular dysfunction 5 to 21 days after
MI. No effect on all-cause mortality was demonstrated, and
the investigators concluded that despite the reduction in
arrhythmic death rate, routine use of prophylactic amioda-
rone after MI was not warranted because of the lack of
demonstrable effect on total mortality (35). The CAMIAT
trial was designed to test the effect of amiodarone on the risk
of arrhythmic death or resuscitated VF among survivors of
MI with frequent or repetitive PVCs or nonsustained VT.
In this trial, amiodarone reduced the incidence of arrhyth-
mic death and resuscitated VF (38.2%, p 5 0.029). These
reductions were greatest among patients with congestive
heart failure (CHF) (36). A limitation of this study was the
lack of assessment of left ventricular dysfunction, a known
predictor of arrhythmic events and mortality in post-MI
patients. Both trials have demonstrated the safety of amio-
darone use in post-MI patients, and that its potential benefit
is best seen in high-risk patients taking beta-blockers. A
summary of all the post-MI amiodarone trials is provided in
Table 1.
The GESICA (Grupo de Estudio de la Sobrevida en la
Insuficiencia Cardiaca en Argentina) and CHF-STAT
(Survival Trial of Antiarrhythmic Therapy in Congestive
Heart Failure) trials assessed the effect of amiodarone on
total mortality in patients with left ventricular dysfunction
regardless of the etiology (See Table 1). The GESICA trial
compared low-dose amiodarone with standard therapy in
patients with severe CHF who did not have symptomatic
ventricular arrhythmias. The mortality rate in the treatment
group was 33.5% compared with 41.4% in the control
group, and was independent of the presence of nonsustained
VT at baseline (37). The investigators concluded that
amiodarone was beneficial to patients with CHF. The
CHF-STAT trial evaluated amiodarone versus placebo in
674 patients with CHF, cardiac enlargement, a left ventric-
ular ejection fraction of 40% or less and 10 or more
premature ventricular contractions per hour. The cause of
heart failure was ischemic in 71% of patients. Although
amiodarone reduced the frequency of PVCs and nonsus-
tained VT, it did not reduce the incidence of sudden death
or prolong survival. Subgroup analysis showed a trend
toward improvement in survival in patients with nonisch-
emic cardiomyopathy, but the difference did not reach
statistical significance. Moreover, in the subgroup with
nonsustained VT before randomization and in the subgroup
with suppression of ventricular ectopy by amiodarone, no
survival benefit was apparent (38). The disparity between
GESICA and CHF-STAT could have been be due to
differences in the patient populations. In the GESICA trial,
61% of the patients had nonischemic cardiomyopathies,
compared with 29% in CHF-STAT, suggesting that pro-
phylactic amiodarone may be more beneficial to patients
with nonischemic cardiomyopathy.
The Multicenter Automatic Defibrillator Implantation
Trial (MADIT) tested the hypothesis that prophylactic
implantation of a cardioverter-defibrillator (ICD) in high-
risk patients with nonsustained VT, coronary artery disease
and a positive electrophysiologic study would improve
survival when compared with conventional medical therapy.
During electrophysiologic testing, sustained VT or fibrilla-
tion had to be reproducibly induced with programmed
stimulation and not suppressed with intravenous procain-
amide. Patients were then randomized to receive either
“conventional antiarrhythmic therapy” or an ICD. The
safety and monitoring committee terminated the study
prematurely because of excess mortality with conventional
antiarrhythmic therapy (See Table 1). Many critics argue
that this trial was not a fair comparison between antiar-
rhythmic drug therapy and ICD therapy for the following
reasons: 1) Suppression with procainamide was considered
an exclusion criterion, thus eliminating patients that may
have done well on other conventional drugs such as amio-
darone; 2) Twenty-three percent of patients randomized to
conventional therapy were on no antiarrhythmic medica-
tions and 44% of the ICD group were taking an antiar-
rhythmic agent, giving the impression that this was almost
a comparison between ICD combined with antiarrhythmic
therapy and no therapy at all; 3) Beta-blockers were used in
27% of patients with an ICD implant and only in 5% of
patients receiving conventional therapy; 4) Conventional
drug therapy was not EP guided. Despite these limitations,
the Food and Drug Administration recently approved the
implantation of ICD in MADIT-like patients. In the
authors’ opinion, patients with coronary artery disease, left
ventricular dysfunction and nonsustained VT should un-
dergo programmed electrical stimulation, and if inducible,
receive an ICD implant (39).
The Coronary Artery Bypass Graft (CABG) Patch Trial
was based on the hypothesis that ICD implantation at the
time of CABG surgery would improve survival in 900
patients with depressed ejection fractions and positive pre-
operative signal-averaged electrocardiograms. During an
average follow-up of 32 months, 101 patients with ICDs
died, compared with 95 from the control group. This
difference was not significant, and the authors concluded
that prophylactic ICD therapy was of no benefit in this
population (see Table 1) (40). The findings in this trial are
clearly different from the MADIT, and we think this is best
explained by the following: 1) All CABG-PATCH patients
underwent revascularization, which could have altered the
electrical milieu responsible for future arrhythmic events,
and 2) signal-average electrocardiogram is probably a poor
marker of arrhythmic events in comparison with spontane-
ous or induced VT.
Antiarrhythmic therapy guided by invasive electrophysi-
ologic testing has historically been used to treat patients
with nonsustained ventricular arrhythmias after MI who
have inducible VT at electrophysiologic study, but this
approach has never been tested systematically. It has been
suggested that a favorable response to antiarrhythmic ther-
apy simply identifies a lower risk population, and no direct
benefit is gained by treatment with antiarrhythmic drugs
625JACC Vol. 34, No. 3, 1999 Welch et al.
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(24). The Multicenter Unsustained Tachycardia Trial (now
in follow-up) will address this issue and is based on the
following two hypotheses. First, EP-guided antiarrhythmic
therapy can reduce sudden death and overall mortality in
survivors of acute MIs; and second, the SAECG can
identify the highest risk patients (41). The entry criteria
required that patients have coronary artery disease, a left
ventricular ejection fraction of 40% or less and nonsustained
VT. All candidates underwent SAECG and baseline elec-
trophysiology study. Patients with no inducible arrhythmia
are being followed without antiarrhythmic therapy. Patients
with inducible VT were randomized to receive either no
therapy or antiarrhythmic therapy guided by serial electro-
physiologic testing (or an ICD if VT remained inducible
and hemodynamically significant despite drug treatment).
Initially, up to three drug tests were performed before
implantation of a defibrillator or initiation of amiodarone
therapy, but this was reduced to a single drug test before
completion of enrollment. The first drug choice was ran-
domly assigned as class IA (quinidine, procainamide or
disopyramide), class IC (propafenone) or class III (sotalol)
(41). Patients who remained inducible on the initial antiar-
rhythmic drug usually received either amiodarone or an
ICD, although many different drugs and drug combinations
were specified as treatment options in the protocol. Enroll-
ment was completed for MUSTT in 1997, and follow-up
continues. Of note, preliminary data show that the cycle
length, frequency and duration of nonsustained VT do not
predict induction of VT or VF by programmed stimulation
(42).
Summary of primary prevention trials. Several recom-
mendations can be made based on the results of these
primary prevention trials in patients with coronary artery
disease. First, the use of class I antiarrhythmic drugs to
suppress frequent ventricular ectopy is associated with in-
creased mortality and is therefore contraindicated. Second,
the one large trial of d-Sotalol (SWORD) was terminated
early because of excess mortality, and thus the empiric use of
d-Sotalol cannot be recommended. Third, high-risk pa-
tients with low ejection fractions, nonsustained VT and
inducible VT not suppressed by procainamide appear to
benefit from ICD therapy. Fourth, the use of amiodarone
for primary prevention of sudden death in patients with
either ischemic or nonischemic cardiomyopathies is not
associated with an adverse outcome, but likewise, has not
been proved to confer a survival benefit. A recent meta-
analysis of all 13 randomized primary prevention trials using
amiodarone reported a 13% overall reduction in total mor-
tality and a 29% reduction in arrhythmic death. The authors
acknowledged the limitations of meta-analyses, but sug-
gested that amiodarone was unlikely to be pro-arrhythmic,
and that in high-risk patients, amiodarone use was justified
(43).
In summary, it is the authors’ opinion that survivors of an
MI should have an assessment of ejection fraction, and if the
ejection fraction is reduced, a 24-h Holter monitor no
earlier than 4 to 5 days after the infarction. We chose Holter
monitoring because the results of the MADIT and CABG-
PATCH trials suggest that spontaneous VT is a better
marker than SAECG for predicting future arrhythmic
events. Definite recommendations for the clinical use of
signal-averaged electrocardiogram should await the publi-
cation of the MUSTT results. Patients with low ejection
fractions and nonsustained VT may be treated empirically
with amiodarone, recognizing that amiodarone therapy for
this patient population is still controversial. Referral for an
electrophysiology study for further risk stratification and
possible ICD therapy is a reasonable approach in these
patients. In our opinion, patients with inducible VT should
have an ICD implanted. The results of the MUSTT trial
will shed some light on the role of EP-guided therapy and
how it compares with ICD therapy or no therapy at all in
these high-risk patients.
THERAPY OPTIONS FOR PATIENTS
WITH VENTRICULAR ARRHYTHMIAS
Patients who present with sustained VT, sudden cardiac
death or syncope in the setting of significant structural heart
disease are generally a high-risk group, and little controversy
exists that these patients should be aggressively evaluated
and treated. The results of the Antiarrhythmics Versus
Implantable Defibrillators (AVID) trial (described in the
next section), as well as the results of many smaller second-
ary prevention trials, suggest that the use of ICDs can
decrease the risk of sudden death even when compared with
treatment with class III drugs such as amiodarone. For this
reason, antiarrhythmic drug therapy guided by serial elec-
trophysiologic testing or serial holter monitors is used less
often now by electrophysiologists in clinical practice and is
usually reserved for patients with refractory arrhythmias
leading to frequent defibrillator shocks.
Catheter ablation techniques may also provide a cure for
VT patients in selected cases. In bundle branch reentry
tachycardia, where the tachycardia is due to macroreentry
within the His Purkinje system, radiofrequency ablation of
the right bundle branch is curative (44). This type of VT
usually has a left bundle branch block/superior axis mor-
phology and occurs in patients with dilated cardiomyopathy.
Patients with “normal heart” idiopathic sustained VT also
enjoy great success rates, with up to 90% of patients cured
(45,46). In selected cases of sustained, monomorphic VT
occurring in the setting of coronary artery disease, radiofre-
quency ablation can be successful in up to 73% of patients
(47). This type of treatment; however, remains an adjunc-
tive therapy in patients with ischemic VT.
Surgical resection represents a potential cure for VT in
well-selected cases, but is associated with substantial mor-
tality (up to 20%) (48,49). Surgical resection for VT has
been largely replaced by ICD therapy (see below), but
remains an option at selected centers, especially when
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surgical resection of a left ventricular aneurysm is also
indicated due to hemodynamic compromise.
Secondary prevention trials. A number of studies pub-
lished before the widespread use of ICDs showed that
suppression of inducible ventricular arrhythmias during
treatment with an antiarrhythmic drug was associated with
improved survival (50). Of the patients who were rendered
noninducible with antiarrhythmic therapy, arrhythmic event
rates ranged from 11% to 31%. Conversely, arrhythmic
event rates range from 35% to 88% for patients with
inducible VT not suppressed with EP-guided therapy who
subsequently received empiric antiarrhythmic drug treat-
ment (Fig. 3) (21–24,41). Nearly all clinical arrhythmia
events occurred in patients with inducible arrhythmias and
left ventricular ejection fractions below 40%. Some investi-
gators have questioned whether the survival benefit is derived
from the antiarrhythmic drug, or whether the response to
antiarrhythmic drugs has simply identified a population already
at lower risk (24). Programmed stimulation may also be used to
determine whether antitachycardia pacing (as delivered by an
ICD) will be an effective therapeutic modality.
For several years, experts debated the relative merit of
Holter-guided versus EP-guided antiarrhythmic drug ther-
apy for patients with ventricular arrhythmias or for cardiac
arrest survivors. Mitchell et al. (51) demonstrated a statis-
tical benefit of EP-guided therapy, although the numbers
were relatively small (57 patients). The noninvasive ap-
proach required fewer drug trials and fewer hospital days,
but the two-year actuarial probability of recurrence was
0.50 6 0.10 for the noninvasive technique versus only the
0.20 6 0.08 for the EP-guided approach (p 5 0.02). In
contrast, Graboys et al. (52) showed that patients with
sustained arrhythmias treated with antiarrhythmic drugs
had improved survival if ventricular ectopy was reduced
during therapy as assessed by 24-h ambulatory monitoring.
The relative advantage of invasive over noninvasive tech-
niques for predicting antiarrhythmic drug success became
less clear after the publication of the Electrophysiologic
Study Versus Electrocardiographic Monitoring (ESVEM)
trial (53). ESVEM included 486 patients who had been
resuscitated from cardiac arrest or who had documented
sustained VT or syncope. In addition, inducible VT at
electrophysiology study and an average of 10 or more PVCs
per hour on Holter monitor were required for enrollment.
These patients were randomized to EP-guided therapy or
Holter-guided therapy. No significant difference in survival
between the two groups occurred over six years, although an
acceptable response to medication occurred more frequently
in the patients treated with Holter-guided therapy. Of the
seven drugs used in ESVEM (imipramine, mexiletine pir-
menol, procainamide, propafenone, quinidine and sotalol),
sotalol was more effective than the other antiarrhythmic
drugs in preventing death or recurrence of arrhythmias,
regardless of the method of therapy guidance used (54). The
ESVEM results should be interpreted with caution. First,
the arrhythmia recurrence rate was 50% in both groups at two
years, suggesting that neither method for serial testing was very
effective in this patient population. Second, both frequent
PVCs and inducible VT had to be present for enrollment,
which limits the results of this trial to only a fraction of patients
with sustained VT or VF. Third, only 22% of patients enrolled
had a history of true cardiac arrest, and neither amiodarone nor
implantable defibrillators were used in the trial (53).
The debate regarding EP-guided antiarrhythmic drug
therapy continued with the publication of the CASCADE
study (Cardiac Arrest in Seattle: Conventional Versus
Amiodarone Drug Evaluation). The CASCADE compared
conventional drug therapy versus amiodarone, randomly
assigning outpatient cardiac arrest patients to either empiric
amiodarone therapy or treatment with other antiarrhythmic
drugs (including class I agents) guided by electrophysiology
testing, Holter recording or both (55). The results of
CASCADE are somewhat difficult to interpret, because
placement of an ICD became standard in all groups in the
middle of the trial. However, patients treated with empiric
amiodarone had improved survival free of cardiac death,
resuscitated cardiac arrest or syncopal episode with ICD
shock. Steinbeck et al. (56) compared EP-guided antiar-
rhythmic drug therapy with beta-blocker therapy in patients
with symptomatic, sustained ventricular tachyarrhythmia.
Patients with inducible arrhythmia were randomly assigned
to receive either EP-guided drug therapy with serial testing
or empiric treatment with metoprolol. The incidence of
sudden death and symptomatic arrhythmia after two years
was similar in both groups. The authors concluded that
EP-guided therapy did not improve the overall outcome of
patients with sustained ventricular arrhythmias. This con-
clusion should be interpreted with caution because 52% of
patients assigned to EP-guided therapy remained inducible
despite testing and were discharged home on antiarrhythmic
drug therapy. Recurrent arrhythmia and sudden death was
Figure 3. Arrhythmic events in patients with coronary artery disease
and nonsustained VT who had positive EP studies. The patients with
non-EP-guided therapy often had persistently inducible VT after one
or more drug trials. Adapted from references 21, 23 and 50.
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highest in this group compared with those who became
noninducible. If patients with persistently inducible VT had
received ICD therapy, the outcome in the EP-guided group
would have probably been different.
Until the late 1980s, antiarrhythmic drug therapy was the
only option for patients with malignant ventricular arrhyth-
mias (see antiarrhythmic drug therapy section above), but
evidence is accumulating that ICDs substantially improve
survival in many different patient populations. Data from
case-controlled and historical-controlled studies show clear
evidence of reduction in sudden cardiac death, although
overall mortality changes have been difficult to demonstrate.
Certain high-risk groups (such as patients with low ejection
fractions) may benefit more than others. One study of
cardiac arrest survivors with impaired left ventricular func-
tion demonstrated that ICD therapy improved survival
compared with conventional therapy from 82.1% to 94.3%
at 1 year and 45.3% to 69.3% at 5 years (57). Another study
estimated that the ICD improved survival from 72% to 89%
at one year and from 49% to 65% at three years (58).
Despite these reports of improved survival, concern was
raised that overall mortality (as opposed to sudden cardiac
death mortality) was not substantially changed by ICD
therapy (59,60). In view of these doubts, and the substantial
cost of ICD therapy, the National Institutes of Health
sponsored the AVID trial. AVID was designed to deter-
mine whether placement of an ICD or antiarrhythmic drug
therapy resulted in longer survival in patients with life-
threatening ventricular arrhythmias. The entry criteria for
randomization in AVID included resuscitated VF or VT,
although patients with VT were required to have syncope or
a left ventricular ejection fraction of #40% with hypoten-
sion or angina. Coronary artery disease was not an inclusion
criterion. Patients were randomized to placement of an ICD
or to antiarrhythmic therapy. In the antiarrhythmic therapy
arm, patients with any contraindication to sotalol were treated
with amiodarone. The remaining patients were randomized to
sotalol (EP or Holter-guided) versus amiodarone. At dis-
charge, only 13 patients (2.6%) had adequate arrhythmia
suppression with sotalol and remained on the drug. The study
was terminated prematurely because of a 26% to 31% reduction
in mortality over 1 to 3 years with ICD therapy (61).
The Cardiac Arrest Study-Hamburg (CASH) trial in-
cluded sudden death patients with documented VT or VF
and was designed to compare ICD therapy with treatment
with antiarrhythmic drugs (unpublished results). Patients
were randomized to receive an ICD, propafenone, meto-
prolol or amiodarone. The propafenone arm was terminated
early because of excess mortality compared with ICDs (29%
vs. 11% at one year) (62). At two years, the mortality rate for
patients with an ICD was 12.1% compared with 19.6% for
antiarrhythmic drugs (combined amiodarone and metopro-
lol groups). The difference was statistically significant, but
because of statistical corrections for multiple comparisons,
differences between mortality in the ICD group versus the
individual drug groups were not significant. Of note, mor- Ta
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tality rates in the amiodarone group and the metoprolol
group were identical. In the Canadian Implantable Defi-
brillator Study (CIDS), patients with VF, cardiac arrest or
sustained VT were randomized to ICD versus amiodarone
therapy. The primary end point was all-cause mortality. Pre-
liminary results, presented recently, showed a modest reduction
of almost 20% with ICD therapy that did not reach statistical
significance. Both therapies were well tolerated. A summary of
the secondary prevention trials is provided in Table 2.
Although the results of the secondary prevention trials
indicate that ICD therapy improves survival in patients with
sustained ventricular arrhythmia, it is our opinion that
EP-guided therapy remains an acceptable treatment option
in certain cases. In patients with sustained VT not associ-
ated with syncope and a left ventricular ejection fraction
.40%, EP-guided therapy is a reasonable approach because
those patients do not strictly meet the AVID inclusion
criteria, and their risk of having a hemodynamically unstable
ventricular arrhythmia is low. Similarly, in AVID-like
patients who do not wish to have an ICD implanted,
amiodarone therapy with serial EP testing may be offered.
EP-guided therapy with amiodarone has not yet been
compared with ICD therapy in this high-risk population. In
our opinion, patients with inducible VT suppressed with
amiodarone therapy are likely to have a good prognosis
because historically, noninducibility with drug therapy has
been associated with a good outcome. However, unless
contraindicated, it is our recommendation to proceed with
ICD therapy in patients who could have been eligible for
entry in the AVID trial.
Conclusions. The treatment of ventricular arrhythmias
remains a challenge. A rational approach to patients with
ventricular arrhythmias or at risk for them must take into
account the predictive value of various risk stratification
algorithms. The lessons taught by the CAST trial should be
kept in mind: that antiarrhythmic drugs are potentially
proarrhythmic and that drug treatment of ventricular ar-
rhythmias may in fact directly harm the patient if under-
taken without knowledge of the risks and benefits of the
drugs. The implantable defibrillator has revolutionized
modern electrophysiology, and the survival benefits of ICD
therapy is at last being verified in prospective multicenter
studies. Randomized trials have shed substantial light on
proper treatment of patients with ventricular arrhythmias,
and will continue to shape the way we care for patients at
high risk for VT and VF.
Reprint requests and correspondence: Mohamed H. Hamdan,
Division of Cardiology (111A), Dallas VA Medical Center, 4500
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